Development & Clinical Validation of a ctDNA-Based MRD Assay in Breast Cancer

• MRD detection using ctDNA represents a promising approach for early relapse prediction in breast cancer
• Observational studies showed MRD is a strong prognostic factor consistently across the subtypes and clinical situations
• Interventional MRD-guided trials are now reshaping treatment paradigms

Speakers:

Yukinori Ozaki

Breast Medical Oncology

Cancer Institute Hospital, Japan Foundation for Cancer Research